Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome (PROG2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01067664|
Recruitment Status : Completed
First Posted : February 11, 2010
Last Update Posted : October 18, 2013
This observational study attempts to investigate the potential role of serum progesterone levels on the day of hCG administration (thus, the end of the follicular phase) on the probability of pregnancy, in patients undergoing IVF with the use of GnRH antagonists and recombinant gonadotrophins.
There has been evidence, that increased serum levels of progesterone are associated with a decreased probability of pregnancy after IVF.
This study will attempt to explore the role of progesterone on the outcome of IVF, by closely monitoring its levels during the late follicular phase.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||130 participants|
|Official Title:||The Effect of Serum Progesterone Levels on the Day of hCG Administration on the Probability of Pregnancy in Patients Treated by IVF Using GnRH Antagonists and Recombinant Gonadotrophins|
|Study Start Date :||May 2009|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2013|
|Patients undergoing IVF with rFSH and GnRH antagonists|
- Clinical pregnancy, defined as ultrasound evidence of fetal heart activity at 6-8 weeks of gestation [ Time Frame: At 6-8 weeks of gestation ]
- Pregnancy (defined as a b-hCG> 25 IU/L) [ Time Frame: 12 days after embryo transfer ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01067664
|Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki|
|Principal Investigator:||Basil C Tarlatzis, MD, PhD||1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki|
|Principal Investigator:||Christos A Venetis, MD, MSc||Unit for Human Reproduction, 1st Dept. of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki|